Vanguard Global Advisers
VRTX icon

Vanguard Global Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Vanguard Global Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272M Sell
547,463
-8,270
-1% -$3.67M 0.13% 116
2026
Q1 		$248M Buy
+555,733
New +$259M 0.13% 119

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Global Advisers's VRTX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, selling an estimated $3.67M and leaving 547,463 shares worth $272M. The position accounts for 0.13% of the portfolio, ranked #116.

Vanguard Global Advisers first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,663 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Vanguard Global Advisers held 547,463 shares of Vertex Pharmaceuticals worth $272M as of Q2 2026.
  • Vanguard Global Advisers sold 8,270 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.67M.
  • Vertex Pharmaceuticals made up 0.13% of Vanguard Global Advisers's portfolio in Q2 2026, its #116 holding.
  • Vanguard Global Advisers first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,663 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.